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EDITORIAL

“Weighing in” on the Framingham Osteoarthritis Study: Measuring Biomechanical
and Metabolic Contributions to Osteoarthritis
C. Thomas Appleton,1 Gillian A. Hawker,2 Catherine L. Hill,3 and Janet E. Pope1
Thirty years ago, Altman et al told us that osteoarthritis (OA) is not a single disease (1). That 1986 description of OA as “a heterogeneous group of conditions that
lead to joint symptoms and signs. . .” remains true today.
But the simple recognition of OA as a group of related but
distinct joint disorders among clinicians and researchers is
hampered by the lack of a clearly accepted set of criteria to
distinguish independent clinical OA phenotypes. Moreover, the description of these clinical OA phenotypes in
molecular, anatomic, and physiologic domains remains a
formidable, yet fundamental task before us in the field of
OA research. Notwithstanding, the blanket term “OA”
should no longer be used in isolation to describe the typical
joint pathology and symptoms of the most common form
of arthritis in humans. An effort should be made in all OA
cases to apply accompanying adjectives to at least describe
the context in which the joint disease arose. Candidate
clinical phenotypes include OA related to joint trauma
(posttraumatic OA), advanced age at disease onset (agerelated/senescent OA), strong family history (inherited/
genetic OA), pain sensitization, inflammatory features,
and metabolic syndrome (metabolic OA) (2). Given that
;25% of the world’s adult population develops metabolic
syndrome (3), the association of metabolic syndrome with
OA is especially alarming.

Metabolic syndrome consists of 4 core features,
variably defined, including hypertension, atherogenic dyslipidemias, visceral obesity, and insulin resistance. The
most recent metabolic syndrome definitions from the US
National Cholesterol Education Program Adult Treatment
Panel III and the International Diabetes Federation were
presented in 2005. Regardless of the definition of metabolic syndrome, a clear link between metabolic syndrome
and OA has been established in many different studies.
Analyses of Third National Health and Nutrition Examination Survey (NHANES-III) data show that metabolic syndrome prevalence is higher among people with OA than
those without OA (59% versus 23%, respectively) and that
this form of OA occurs in younger age groups (ages
45–65 years) than age-related OA (4). The individual components of metabolic syndrome are also associated with
excess OA risk. For example, in the Japanese Research on
Osteoarthritis Against Disability (ROAD) study, the risk
of OA increased with each additional component of metabolic syndrome (5), although that was a cross-sectional
analysis without adjustment for body mass index (BMI).
The nature of the interaction between metabolic
syndrome and OA remains unresolved. It is unclear
whether the most important link is due to an influence of
OA on metabolic syndrome (e.g., decreased mobility due
to OA leads to obesity and therefore metabolic syndrome),
vice versa (abnormal joint loading—with or without metabolic derangement—fuels OA pathophysiology), or if a
common set of risk factors exist which drive both conditions in parallel. A shared etiology in the latter case would
suggest that metabolic OA is an underrecognized fifth (or
sixth) feature of metabolic syndrome rather than a separate
condition per se, as some have suggested (6). As is often
the case, the answer may lie in a combination of these possibilities. But the reliance on prevalence data and crosssectional analyses in most OA/metabolic syndrome studies

1
C. Thomas Appleton, MD, PhD, FRCPC, Janet E. Pope,
MD, MPH, FRCPC: Western University and St. Joseph’s Health
Care, London, Ontario, Canada; 2Gillian A. Hawker, MD, MSc,
FRCPC: University of Toronto, Women’s College Research Institute,
Women’s College Hospital, and Institute for Clinical Evaluative
Sciences, Toronto, Ontario, Canada; 3Catherine L. Hill, MBBS, MD,
MSc, FRACP: The Queen Elizabeth Hospital, Woodville, South
Australia, Australia, and the Health Observatory, University of
Adelaide, Adelaide, South Australia, Australia.
Address correspondence to C. Thomas Appleton, MD, PhD,
FRCPC, St. Joseph’s Health Care London, 268 Grosvenor Street, London,
Ontario N6A 4V2, Canada. E-mail: tom.appleton@sjhc.london.on.ca.
Submitted for publication January 14, 2017; accepted in
revised form March 2, 2017.

1127

1128

makes it difficult to resolve such “chicken-or-the-egg”
questions. Nevertheless, the balance of the literature suggests that metabolic syndrome and increased BMI or body
weight are each associated with an increased risk of incident knee OA especially. Increased BMI or body weight
and metabolic syndrome (given that BMI is a core component) clearly cause increased or abnormal knee joint loading (7). Therefore, the fundamental question that remains
is whether metabolic syndrome increases incident OA risk
purely driven by the biomechanical consequences of
increased body weight, or if metabolic derangement (e.g.,
from increased visceral fat–driven systemic inflammation
or other mechanisms yet to be confirmed) confers additive
risk beyond that explained by biomechanics alone.
In this issue of Arthritis & Rheumatology, Niu et al
(8) present longitudinal data from the Framingham OA
Study, demonstrating an association of preexisting metabolic syndrome and its components with an increased risk
of incident radiographic and symptomatic knee OA over 10
years of follow-up. A dose-response relationship was also
seen for the association of the number of metabolic syndrome components with incident radiographic OA. The
assessment of metabolic syndrome occurred a year or so
before the OA examination. The prospective study design
and inclusion of incident OA outcomes allowed for risk
factors to be determined, in contrast to previous studies
that showed only correlations or associations. The unique
statistical approach for examining the various contributions
to OA development due to BMI versus body weight versus
waist circumference suggested a very high correlation
among these measures, which is useful methodologically
for future studies.
The incidence data presented by Niu et al are particularly noteworthy, since they show that preexisting metabolic syndrome and its components are risk factors for
subsequent symptomatic OA and not just radiographic
OA. Their study also provides circumstantial evidence
supporting the hypothesis that at least one or more of the
metabolic syndrome components may cause OA. Of course,
the increased risk may alternately belie the existence of
common risk factors for both metabolic syndrome and OA,
where OA may be a later-occurring additional component
of metabolic syndrome. However, we feel it is most appropriate to consider metabolic OA as a complication of metabolic syndrome, similar to cardiovascular disease.
Understanding how metabolic syndrome underlies
the manifestation of metabolic OA is confounded further
by the duality of pathobiology and biomechanics impelling
OA pathophysiology. Obesity is the only metabolic syndrome component that is consistently associated with OA
across most studies, suggesting that increased weight plays
a role in OA development through increased joint loading.
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However, increased joint loading may not fully explain the
effects of metabolic syndrome on all aspects of metabolic
OA, since hand OA is also associated with obesity with or
without other metabolic syndrome components (9) and is
independent of abnormal joint loading. It should be noted,
though, that the hypothesis that hand OA is related to obesity remains a subject of controversy, in part due to the
cross-sectional design of the studies in which a significant
association was found. Nevertheless, failure to adjust for
any contribution of increased joint loading in knee OA due
to increased body weight in metabolic syndrome will overestimate the contribution of metabolic processes to metabolic OA.
Teasing out the relative contributions of abnormal
biomechanics versus metabolic derangement to the development of metabolic OA is an essential step that we must
achieve to realize the best approaches to treatment. Niu
et al astutely raise this issue in the Framingham OA analysis and attempt to isolate the contribution of metabolic
derangement due to metabolic syndrome from abnormal
joint loading by adjusting for BMI or body weight. Such
adjustment nullified the association between incident
radiographic OA and symptomatic OA with metabolic syndrome and each of the metabolic syndrome components,
with the exception of diastolic blood pressure, which
remained significantly associated with symptomatic OA.
Associations between metabolic syndrome components
and knee OA after adjustment for BMI were also nullified
in the Korean National Health and Nutrition Examination
Survey (10), among others.
Unfortunately, BMI and body weight are not ideal
surrogates for joint loading, especially in metabolic syndrome, due to a close correlation with central obesity.
Indeed, the correlation of BMI and body weight with central obesity is strong (Niu et al calculate a Pearson’s correlation coefficient of 0.84–0.88). Measurement of body
composition, which better delineates the contribution of
fat and muscle to body mass, has led to interesting findings
in knee OA. A recent study has suggested that the effect of
BMI in asymptomatic knee OA is predominantly mediated
by fat mass (and not lean mass), suggesting that differentiating between fat mass and weight may also be beneficial
in predicting incident OA (11). Moreover, adjustment for
body composition rather than BMI or body weight may be
a better approach in future studies, which will be required
to determine if a significant contribution to incident OA
risk from fat mass–driven metabolic derangement truly
does exist beyond biomechanics.
In addition to adding to body weight, central (visceral) obesity is strongly linked to important metabolic
functions. For example, beginning with the discovery of
leptin in 1994 (12), adipose tissue has been identified as

EDITORIAL

having an important endocrine function through the secretion of adipokines. In the Invecchiare in Chianti (Aging in
the Chianti area; InCHIANTI) study, high leptin levels
were associated with metabolic syndrome in obese and
nonobese patients (13), and high levels of leptin were associated with incident radiographic knee OA in the American Study of Women’s Health Across the Nation (SWAN)
(14). Central obesity is also tied to the development of
metabolic syndrome components, including dyslipidemia
and insulin resistance. So, while central obesity contributes
to abnormal joint loading via increased body weight, it may
also influence joint homeostasis via systemic metabolic
derangements. Since BMI/weight (which captures central
obesity) encompasses both metabolic and mechanical
loading variables, it follows that adjustment for BMI or
body weight in studies may simultaneously adjust for both
joint loading and metabolic factors associated with central
obesity. Even though the intention is to adjust for abnormal joint loading in isolation, this strategy limits the ability
to draw conclusions about the relative contributions of
abnormal joint loading versus metabolic syndrome (or its
components) with incident OA. Inventively, Niu et al try to
address this issue with residuals of waist circumference
after removing variation caused by BMI and body weight,
but this also negated any associations with incident OA.
What is needed is an alternative factor for adjustment that more precisely estimates the magnitude of
abnormal joint loading without encompassing any metabolic effects of adipose tissue. An ideal measure would be
to quantify knee joint load directly, but this is quite difficult to measure externally, and force-measuring joint
implants are expensive, are invasive, and would not be feasible for incident radiographic OA or symptomatic OA
studies. Knee adduction moment (KAM) is a close surrogate of medial tibiofemoral compartment force, especially
components of KAM such as peak KAM. Changes in
peak KAM in obese patients are due to weight and not
obesity distribution, making this a suitable alternative
measure to use for adjustment of joint loading (7). Future
studies exploring associations between metabolic syndrome and OA could include and adjust for KAM and
compare with adjustment for BMI and body weight.
There are some limitations to the study by Niu et al.
Despite the large sample size, incident OA was rare, so the
borderline effect of blood pressure on incident OA may
have been due to the study not having adequate power to
detect a more robust effect. Moreover, all knee OA was
combined (medial, lateral, and patellofemoral). The latter
may have been a limitation since perhaps medial OA is
affected more by metabolic syndrome than patellofemoral
OA. The numbers of different subsets with incident OA
were too small to allow for subset calculations for robust
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answers regarding associations with metabolic syndrome.
The date of onset of OA could not be precisely determined
since subjects were only examined at fixed dates. Since OA
symptoms might motivate participants to make lifestyle
changes (e.g., to lose weight), future studies need to carefully consider how to take such prior exposures into
account for adjustment. There was a protective effect of
glucose (after adjustment for BMI), which warrants further
research since this could be real or spurious due to the use
of numerous statistical tests.
Considering the likely confounding of body weight
between mechanical and metabolic processes, the fact that
any component of metabolic syndrome remained significantly associated with symptomatic OA after adjusting for
BMI and body weight argues strongly for a metabolic
driver of OA pathophysiology. A 2012 cross-sectional
study in 352 OA patients showed that 60% of patients with
prevalent OA had hypertension after correcting for age
and BMI (15). In NHANES-III, 77% of subjects with OA
had hypertension versus 30% of those without OA (4).
Again, this does not help us to sort out whether it’s the
chicken (OA-related loss of mobility causing hypertension)
or the egg (hypertension leading to OA). Mechanistically,
subchondral ischemia is the best described hypothesis for
hypertension contributing directly to OA pathogenesis.
Narrowing of subchondral vessels may reduce nutrient
exchange and devitalize the overlying articular cartilage
(16) or stimulate apoptosis of osteocytes and subsequent
osteoclast activation and subchondral bone remodeling
(17). Much work is left to be done in this area to delineate
the mechanisms involved, but clinical studies investigating
the impact of antihypertensive therapy in patients with
hypertension and comorbid metabolic OA would offer
insights.
Metabolic OA should be considered and studied
separately from other types of OA. The development or
updating of classification criteria would aid significantly in
defining metabolic OA. While such a task is best suited to a
classification criteria committee, possible minimum criteria
to consider might include a) the presence of metabolic syndrome according to an accepted definition, b) symptomatic
OA and/or radiographic OA, and c) exclusion of alternative
etiologies such as prior joint trauma, family history of
genetic OA, advanced age at onset (e.g., .75 years), and
underlying comorbid risks (e.g., inflammatory arthritis,
hemochromatosis, calcium pyrophosphate deposition disease, etc.). Adjustment for confounders is a key issue in
clinical studies, but biomechanics are especially important
in OA and musculoskeletal diseases. Thus, working with
our expert colleagues in OA biomechanics research continues to be a vital collaboration in our field. OA and metabolic syndrome are complex diseases with an unresolved
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etiology, but the work presented by Niu et al further
emphasizes the link between these conditions.
Whether metabolic OA should be considered a
component of metabolic syndrome is still open for debate,
but Niu et al have provided data on incident OA in the setting of preexisting metabolic syndrome, the Framingham
OA Study, suggesting that OA may be a consequence of
metabolic syndrome rather than the reverse. Carefully
designed future studies are still required to determine the
relative impact of increased body mass in metabolic syndrome on joint loading versus metabolic derangements
(including systemic inflammation). Such future studies
should be a top priority for our field. Studies employing a
life course approach including past history of elevated BMI
(e.g., obesity during childhood and early adulthood) are
also needed. Ruling in or out a clinically important impact
of altered metabolism on incident OA risk independent of
biomechanics would be a significant breakthrough in our
understanding of metabolic OA and other OA phenotypes.
It would also provide a strong foundation for the development of rational treatment approaches for this pervasive
and disabling disease.
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